FDA declines approval of Lipocine’s oral drug Tlando for third time
Category: #health  By Mateen Dalal  Date: 2019-11-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA declines approval of Lipocine’s oral drug Tlando for third time

FDA declines approval of Lipocine’s oral drug Tlando for third time

Reportedly, the oral drug Tlando was first declined  approval by FDA in the year 2016.

The U.S. Food and Drug Administration (FDA)  declined the approval of oral drug Tlando, developed by Lipocine Inc. for the third time. The drug has been developed to treat a condition, which results in lesser production of male sex hormone. Tlando has been developed to restore normal testosterone levels in male patients with absence or deficiency of testosterone.

This rejection of approval has led the shares of the company to drop by 34%.

As per reliable sources, FDA informed through a letter that the application can not be accepted in its present form as the trial conducted Lipocine could not meet three secondary goals.  These three objectives were designed to evaluate if higher levels of testosterone could risk safety of patients.

Apparently, the decision is the third regulatory setback for Lipocine's Tlando over the period of three years.

Reportedly, the oral drug Tlando was first declined approval by FDA in the year 2016. Later, in 2018, approval for the same  was rejected again for a dosing irregularity. The regulatory body requested for more information to assess whether or not the drug could raise blood pressure in patients.

Lipocine has been struggling to introducing Tlando as a safer substitute to topical therapies, which can cause accidental transference of testosterone.

Sources close to the matter informed that FDA did not find any specific issues related to the chemical composition and manufacturing of Tlando. Lipocine reportedly stated that the company is looking forward to requesting a meeting with FDA soon to ascertain the necessary steps required  for the approval of the drug.

For the record, the U.S. Census Bureau anticipates that around 21.7 million male population in the United States aged between 30-79 years may experience low testosterone levels. The condition can cause decreased muscle mass, loss of libido, depression, and fatigue.
 

Source link:

https://www.thisismoney.co.uk/wires/reuters/article-7672717/FDA-rejects-Lipocines-testosterone-drug-time.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...

Snapchat announces the launch of in-app TikTok competitor Spotlight
Snapchat announces the launch of in-app TikTok competitor Spotlight
By Mateen Dalal

Snapchat, an American multimedia messaging platform, has reportedly launched a new section of its application called Spotlight. The new feature will offer surface video content and will allow the company to compete with Chinese video sharing platform...